Overview

Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients

Status:
Completed
Trial end date:
2017-09-27
Target enrollment:
Participant gender:
Summary
This is a sequential efficacy and safety study in pediatric patients with type 1 diabetes. Subjects will be administered insulin to induce a low normal glycemic state and will then receive an age-appropriate dose of G-Pen (glucagon injection) in a clinical research center (CRC) or comparable setting.
Phase:
Phase 3
Details
Lead Sponsor:
Xeris Pharmaceuticals
Collaborators:
The Emmes Company, LLC
The EMMES Corporation
Treatments:
Glucagon
Glucagon-Like Peptide 1